Euro Biotechnology

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector …

For some migraine sufferers, bright lights or loud sounds are enough to touch off an attack. For others, stress sparks the onset of pain. Bright lights, loud sounds, stress: Migraine triggers vary from one patient to another. But a common element is the abundance of a pain-inducing protein in the blood.

During a migraine attack, nerves release this protein, called calcitonin gene-related peptide (CGRP). A number of companies are developing drugs to block CGRP and stop migraine pain before it starts. The most advanced of these experimental migraine prevention drugs, from Amgen (NASDAQ: AMGN), is expected to receive an FDA… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

Without much fanfare, Amazon has managed to build a billion-dollar advertising business.

That’s not so surprising when one considers that, depending on who you ask, roughly 50% of consumers in the US start a product search on the company’s site or in its mobile app, and many more consult Amazon before finalizing a purchasing decision.

Read more…

At first blush, the $66 million Series B round that startup FogPharma is announcing this morning seems standard fare, particularly this year, when private biotechs have raised gobs of cash hand over fist. But a closer look shows careful steps by an academic-turned-executive, Greg Verdine, to develop the type of company he wants. He’s amassed an unusual array of hand-picked investors who, he says, will largely let him maintain control of his company.

FogPharma is developing an unproven, new class of medicines called “cell-penetrating mini-proteins,” which combine attributes of small molecules and biologics, to try to get at drug targets… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesOpening Date: Deadline: Tue, 11 Sep 2018 17:00:00 (Brussels local time)Modification Date: Wed, 16 May 2018Latest information: Deadline 19/04/2018: 19 proposals were submitted as follows:

• LC-SC3-CC-4-2018 (CSA): 10 proposals received

• LC-SC3-RES-2-2018 (RIA): 9 proposals received

Joseph Yanchik has resigned as president and CEO Aileron Therapeutics (NASDAQ: ALRN) after 12 years at the Cambridge, MA, biotech company. He has also stepped down from the company’s board of directors. Aileron gave no reason for the changes. John Longenecker, founder and president of biopharmaceutical consulting firm JPL Biotech, has been named interim CEO. Aileron develops drugs that target p53, a tumor suppressor protein. The company’s lead drug, ALRN-6924, is being tested in multiple clinical trials as a treatment for acute myeloid leukemia, advanced myelodysplastic syndrome, and peripheral T-cell lymphoma.

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

Trace Sheehan, writer and producer of the highly-acclaimed documentary film Food Evolution, will be a keynote speaker at BIO’s International Convention in Boston, the Biotechnology Innovation Organization (BIO) announced today.

Since its premier in November 2016, Food Evolution has contributed to a robust discussion about science, facts, and food. The film focuses on the GMO debate because the filmmakers found it to be emblematic of the public misunderstanding about the science of food and food sustainability. In his keynote on Tuesday, June 5, Sheehan will share his experience in making the film and explain how the process influenced his own opinions along the way.

Other food and ag-related programming to note:

On Monday, June 4, BIO will host “One Health Day,” a half-day of speakers and panel discussions focusing on how the One Health concept – the interconnectivity of human, animal and environmental health – can help address today’s greatest challenges. The program starts with a keynote presentation and panel introducing the One Health concept before diving right into an exploration of the business case for One Health with a panel of senior leaders from the private sector. The program also looks to global perspectives on One Health policy development and insights into U.S. government funding and research decisions.

On Tuesday, June 5, a second half-day of programming is dedicated to food and agricultural innovation in our “Food, Health, and Environmental Future Day.” This program, featuring Keynoter Trace Sheehan, will include this series of panel discussions:

• A Two-Part Food Innovation Dialogue: Cutting-Edge Food, Health, & Environmental Products and Tools…Coming to a Grocery Store Near You(?)

  Part 1 looks at the landscape of innovation now and on the horizon, including applications of genome editing in animals and plants, microbes for soil health, and more…

  Part 2 brings the food value chain together in a conversation about consumer preferences and trends around sustainability and transparency, and how the innovations discussed in Part 1 will fit in today’s (and tomorrow’s) marketplace.

• Biotech in Our Backyard: New England’s Booming Food and AgTech Innovation Ecosystem
• AgTech Investment: Opportunities for Plants, Animals, Microbes, and Beyond…

On Wednesday, June 6 and Thursday, June 7, BIO’s 2018 International Convention also features a track dedicated to Genome Editing, including programming about Engaging Our Nation and Our World in the Era of Gene Editing and genome editing as The Next Frontier in Agriculture.

Held in conjunction with BIO, CRISPRCon: Conversations on Science, Society and the Future of Gene Editing will take place on June 4-5 at the Boston Seaport Hotel & World Trade center (Separate registration is required).

The BIO International Convention, the world’s premier life sciences event, will take place at the Boston Convention & Exhibition Center, June 4-7.  Hosted by BIO, the 2018 event is expected to attract more than 16,000 attendees and 1,800 exhibitors from 74 countries.

Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-AG-2017Pillar: REC Programme 2014-2020Opening Date: Deadline: Thu, 29 Jun 2017 17:00:00 (Brussels local time)Modification Date: Tue, 15 May 2018Latest information: A Call update document (call results) has been added under Topic conditions and documents, additional documents.

With the Bio-IT World Conference opening today in Boston, San Diego-based Illumina (NASDAQ: [[ticker:ILMN) said it has acquired Edico Genome, a five-year-old startup with  technology to accelerate the readout of next-generation sequencing data.

Illumina withheld terms of the deal in a statement released this morning. But an Illumina spokeswoman later confirmed that Illumina got Edico for $100 million, close to three times the estimated $32 million that Edico raised in venture funding from Qualcomm Ventures, Dell Technologies Capital, and individual investors.

Edico developed technology that combines a specialized processor and chipset with proprietary software to address a bottleneck in the… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesOpening Date: Deadline: Tue, 4 Sep 2018 17:00:00 (Brussels local time)Modification Date: Tue, 15 May 2018Latest information: The submission session is now available for: LC-SC3-JA-1-2018(ERA-NET-Cofund), LC-SC3-JA-2-2018(CSA)